

Do you want to provide
a clear view?

Complete your portfolio for prostate cancer
with B·R·A·H·M·S CgA II KRYPTOR



Prostate cancer:


Relevant for lives, important to have on screen

Most prevalent cancer

in men worldwide

Standard therapeutic approaches
(depending on disease status):

- Watchful Waiting
- Chemo-/Radiotherapy/Surgery
- Hormonal therapy/Androgen Deprivation Therapy (ADT)




Number of prevalent cancer cases in 2018, male, all age¹

Neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer characterized by neuroendocrine differentiated cells. Frequently utilized ADT promotes development of NEPC which usually is resistant to ADT.²

A change in therapy is necessary.



Patients with neuroendocrine prostate cancer often show low PSA but elevated CgA values.²

Elevated CgA indicates neuroendocrine differentiation in prostate cancer.



B·R·A·H·M·S CgA II KRYPTOR:

Therapy monitoring in prostate cancer

Perfect for enabling timely course correction

Shortest time to result



- provides fast, reproducible results
- is significantly less labor intensive
- results are available within 29 minutes and could be reported to clinicians the same day

Superior precision for confident decision

- Exceptional intra- and interassay precision
- homogeneous assay design without any washing or separation step

Broadest measuring range

- less samples have to be diluted
- meets the challenge to provide reliable results over a wide range
- vastly improving the assesement of patients treatment regimens



Advantages of B·R·A·H·M·S CgA II KRYPTOR in prostate cancer:

- **fast**
- **precise**
- **efficient**

The heart of precision in B·R·A·H·M·S


Nobel Prize®-winning principle behind TRACE technology

Homogeneous assay design ensures excellent analytical precision and high reproducibility by eliminating the need of washing and separation steps.

TRACE™ technology provides simultaneous measurement of signal of bound and unbound antibodies, which reduces effects of possible interferences. The unspecific signals are excluded by time resolved measurement.

TRACE: Time Resolved Amplified Cryptate Emission

The unique measurement principle underlying the precision and usability of the Thermo Scientific™ B·R·A·H·M·S™ KRYPTOR™ platforms



Amplified cryptate emission: Cryptate and fluorophore are bound to antibodies that build an immunocomplex around the target analyte. When Europium cryptate is close to fluorophore it donates energy, which lengthens immunocomplex emission well beyond the ones of single antibodies.

In cancer monitoring precision is essential. All changes in concentration of biomarker should be related with a change of the disease and not caused by imprecision of the analyzer.



KRYPTOR platforms

guarantees highly sensitive and specific test results

Ease of use and confidence in results



Accurate and precise




Less waste and reagent consumption



Fast time to result



Biotin-free assay design



Watch the animated visual presentation of TRACE technology:
brahms-instruments.com/technology

The B·R·A·H·M·S KRYPTOR automated random access immunoanalyzers are user-friendly bench-top instruments that can easily be integrated into any laboratory.

- Easy and straightforward laboratory routine with less operator intervention
- Autonomous auto-dilution and separate calibration significantly reduce the need of sample re-run
- Cost reduction due to no repeated measurements



B·R·A·H·M·S KRYPTOR compact PLUS
REF BMKSYS0103



B·R·A·H·M·S KRYPTOR GOLD
REF BMKSYS0201



Take advantage of TRACE technology and measure prostate cancer markers on KRYPTOR:

- **Chromogranin A**
- **Total PSA**
- **Free PSA**

B·R·A·H·M·S CgA II KRYPTOR

The automated immunoassay for Chromogranin A is not only indicated in neuroendocrine tumors but also provides a tool to early identify neuroendocrine differentiated prostate cancer and ADT resistance.

- more safety for the patient
- earlier change of therapy
- more confidence in follow-up

Product	REF
B·R·A·H·M·S CgA II KRYPTOR	839.050
B·R·A·H·M·S Total PSA KRYPTOR	810.100
B·R·A·H·M·S Free PSA KRYPTOR	867.050

Help to refine the view in prostate cancer!



Offer an automated and fast CgA measurement for confident results in the monitoring of all ADT-treated patients

References:

1. Bray, F., et al., CA Cancer J Clin, 2018. 68(6): p. 394-424.
2. Tritschler, S., et al., Pathologie, 2018. 39(4): p. 333-343.

Clinical Diagnostics

Thermo Fisher Scientific
B·R·A·H·M·S GmbH
Neuendorfstr. 25
16761 Hennigsdorf
Germany

+49 (0)3302 883 0
+49 (0)3302 883 100 fax
info.onco@thermofisher.com
www.thermoscientific.com/brahms

Find out more at **thermofisher.com/brahms**

Products are CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.

©2020 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. KRYPTOR is trademark of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.

107728.1